Back to mobile site

Alnylam Pharma (ALNY) Tops Q2 EPS by $1.61

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. RH
3. SPCX
4. NVDA
5. USO
6. MH
7. RKLB
8. NDAQ
9. TFPM
10. BBW

August 1, 2024 8:14 AM EDT

Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of $0.56, $1.61 better than the analyst estimate of ($1.05). Revenue for the quarter came in at $659.8 million versus the consensus estimate of $449.18 million.

2024 Financial Guidance

Full year 2024 financial guidance has been updated as follows:

Provided 2/15/2024

Updated 8/1/2024

Combined net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO1

$1,400 million - $1,500 million

$1,575 million - $1,650 million

Net Product Revenue Growth vs. 2023 at reported FX rates1

13% to 21%

27% to 33%

Net Product Revenue Growth vs. 2023 at CER*

13% to 21%

28% to 34%

Net revenues from collaborations and royalties

$325 million - $425 million

$575 million - $650 million

GAAP R&D and SG&A expenses

$1,900 million - $2,050 million

$2,000 million - $2,150 million

Non-GAAP R&D and SG&A expenses2

$1,675 million - $1,775 million

$1,775 million - $1,875 million

1 Uses June 30, 2024 FX rates including: 1 EUR = 1.07 USD and 1 USD = 161 JPY

2 Primarily excludes $225 - $275 million of stock-based compensation expense from estimated GAAP R&D and SG&A expenses

*CER = Constant Exchange Rate, representing growth calculated as if the exchange rates had remained unchanged from those used in the twelve months ended December 31, 2023. CER is a non-GAAP measure.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings, Maynard Um, Mark Zuckerberg, ARK